JPWO2022056489A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022056489A5 JPWO2022056489A5 JP2023516769A JP2023516769A JPWO2022056489A5 JP WO2022056489 A5 JPWO2022056489 A5 JP WO2022056489A5 JP 2023516769 A JP2023516769 A JP 2023516769A JP 2023516769 A JP2023516769 A JP 2023516769A JP WO2022056489 A5 JPWO2022056489 A5 JP WO2022056489A5
- Authority
- JP
- Japan
- Prior art keywords
- grna
- cells
- cell
- cell population
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078035P | 2020-09-14 | 2020-09-14 | |
| US63/078,035 | 2020-09-14 | ||
| PCT/US2021/050328 WO2022056489A1 (en) | 2020-09-14 | 2021-09-14 | Compositions and methods for cd38 modification |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541457A JP2023541457A (ja) | 2023-10-02 |
| JPWO2022056489A5 true JPWO2022056489A5 (https=) | 2024-09-26 |
| JP2023541457A5 JP2023541457A5 (https=) | 2024-09-26 |
Family
ID=78080565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516769A Abandoned JP2023541457A (ja) | 2020-09-14 | 2021-09-14 | Ｃｄ３８修飾のための化合物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230398219A1 (https=) |
| EP (1) | EP4211244A1 (https=) |
| JP (1) | JP2023541457A (https=) |
| WO (1) | WO2022056489A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| KR20240017367A (ko) * | 2021-06-02 | 2024-02-07 | 메타지노미, 인크. | 클래스 ii, v형 crispr 시스템 |
| EP4426338A2 (en) * | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| US20250295695A1 (en) * | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| KR20260036568A (ko) * | 2023-07-10 | 2026-03-17 | 카스젠 라이프 사이언스 씨오., 엘티디. | 세포 면역 요법용 조성물, 및 방법 |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| EP3556858A3 (en) | 2014-04-09 | 2020-01-22 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating cystic fibrosis |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
| CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| AU2017388753A1 (en) | 2016-12-30 | 2019-07-11 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| US11718659B2 (en) | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CN111918877A (zh) | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
| JP7575271B2 (ja) * | 2018-03-29 | 2024-10-29 | フェイト セラピューティクス，インコーポレイテッド | 操作された免疫エフェクター細胞およびその使用 |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CA3144356A1 (en) * | 2019-06-21 | 2020-12-24 | Function Oncology, Inc. | A genetic pharmacopeia for comprehensive functional profiling of human cancers |
-
2021
- 2021-09-14 JP JP2023516769A patent/JP2023541457A/ja not_active Abandoned
- 2021-09-14 WO PCT/US2021/050328 patent/WO2022056489A1/en not_active Ceased
- 2021-09-14 EP EP21787233.2A patent/EP4211244A1/en not_active Withdrawn
- 2021-09-14 US US18/026,080 patent/US20230398219A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102723347B1 (ko) | 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물 | |
| US20230392131A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
| US20220340936A1 (en) | Programmable polynucleotide editors for enhanced homologous recombination | |
| EP3443088A1 (en) | Grna fusion molecules, gene editing systems, and methods of use thereof | |
| KR20010071227A (ko) | 무세포 키메라플라스티 및 이형이중나선 돌연변이성벡터를 진핵세포에 이용 | |
| US20240318165A1 (en) | Type i-b crispr-associated transposase systems | |
| AU2016244033A1 (en) | CRISPR/CAS-related methods and compositions for treating Duchenne Muscular Dystrophy and Becker Muscular Dystrophy | |
| KR20180031671A (ko) | 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물 | |
| EP4244345A1 (en) | Targeted gene regulation of human immune cells with crispr-cas systems | |
| US20220380758A1 (en) | Type i-b crispr-associated transposase systems | |
| US12319932B2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| Cao et al. | The multiplexed CRISPR targeting platforms | |
| CA3204429A1 (en) | Dna nuclease guided transposase compositions and methods of use thereof | |
| JPWO2022056489A5 (https=) | ||
| WO2023206871A1 (zh) | 一种优化的CRISPR/SpCas12f1系统、工程化向导RNA及其应用 | |
| US20260008827A1 (en) | Nuclease-guided non-ltr retrotransposons and uses thereof | |
| US20230383272A1 (en) | Nucleic acid-guided nucleases and use thereof | |
| TW202425952A (zh) | 脂質奈米顆粒藥物綴合物 | |
| JPWO2022056459A5 (https=) | ||
| JPWO2020150478A5 (https=) | ||
| US20250223577A1 (en) | Hybrid crispr-cas systems and methods of use thereof | |
| US20230383315A1 (en) | Type i crispr-associated transposase systems | |
| WO2021183850A1 (en) | Compositions and methods for modifying a target nucleic acid | |
| JPWO2020237217A5 (https=) | ||
| US20250327054A1 (en) | Reprogrammable isrb nucleases and uses thereof |